Novel agents for sexual dysfunction.
D000287:Administration, Topical; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000527:Alprostadil / Q000008:administration & dosage; D000577:Amides / Q000627:therapeutic use; D015220:Calcium Channels / Q000502:physiology; D018491:Dopamine Agonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016228:Endothelial Growth Factors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D008222:Lymphokines / Q000627:therapeutic use; D008297:Male; D019001:Nitric Oxide Synthase / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D018043:Receptors, Corticotropin / Q000037:antagonists & inhibitors; D044101:Receptors, Melanocortin; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000317:Adrenergic alpha-Antagonists; D000577:Amides; D015220:Calcium Channels; D018491:Dopamine Agonists; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; D018043:Receptors, Corticotropin; D044101:Receptors, Melanocortin; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C108830:Y 27632; D019001:Nitric Oxide Synthase; D000527:Alprostadil